Alternatively, intracellular HER2-targeting compounds might be attractive treatment option in one-third of CRC patients, if cytoplasmic HER2 is really actively involved in carcinogenesis of CRC [29], [33]. The gene discussed is ERBB2; the disease is colorectal carcinoma.